CJC-1295 + Ipamorelin
Research Use Only | Not for Human Consumption
A research blend of CJC-1295 and Ipamorelin, two synthetic growth-hormone-releasing peptides, supplied in lyophilized form.
Blend Components
| Component | CAS# | Formula | Molar Mass |
|---|---|---|---|
| CAS Number: CJC-1295 | Molecular Formula: 863288-34-0 | Molar Mass: C165H271N47O46 | 3647.28 g/mol |
| Ipamorelin | 170851-70-4 | C38H49N9O5 | 711.85 g/mol |
· Free 2-day shipping
A research blend of CJC-1295 and Ipamorelin, two synthetic growth-hormone-releasing peptides
A two-peptide research blend combining CJC-1295, a synthetic GHRH analog, and Ipamorelin, a synthetic pentapeptide ghrelin-receptor (GHS-R1a) agonist. Each component has been examined in preclinical publications for interactions with distinct receptors involved in growth-hormone secretion signaling.
What is CJC-1295 + Ipamorelin?
This blend brings together two peptides with different origin stories. CJC-1295 was developed by ConjuChem Biotechnologies, a Canadian biotech company, in the early 2000s as a long-acting synthetic analog of growth-hormone-releasing hormone (GHRH) for use in preclinical research.
Ipamorelin was characterized in the late 1990s by researchers at Novo Nordisk in Denmark as part of a program investigating selective growth-hormone secretagogues. Published research described it as a pentapeptide agonist at the GHS-R1a (ghrelin) receptor, noted in the literature for its selectivity relative to earlier GH-secretagogue compounds.
Subsequent preclinical publications have examined CJC-1295 for its effects on GH pulse amplitude via GHRH-receptor signaling, and Ipamorelin for its effects on pulse frequency via GHS-R1a signaling. Combination research has examined these dual-mechanism interactions at the level of the GH/IGF-1 axis in laboratory settings.
CJC-1295 and Ipamorelin continue to appear in peer-reviewed preclinical publications investigating growth-hormone-secretagogue pharmacology. This product is intended for research use only.
How should CJC-1295 + Ipamorelin be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Prepared samples must be stored in the fridge to maintain stability, and remain stable for up to 30 days when properly refrigerated.
Certificate of Analysis
Every batch of CJC-1295 + Ipamorelin is tested by ILS Laboratories, an ISO/IEC 17025–accredited lab, for purity, identity, heavy metals, sterility, endotoxin, and a fentanyl screen. The full certificate is below.
CJC-1295 / Ipamorelin · 10mg/10mg
Peptide Purity · HPLC @ 214 nm
99.12% — exceptional research-grade purity
Area-normalized against all peptide-related peaks. Identity confirmed by chromatographic retention-time match to a reference standard.
Every test on this certificate
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with CJC-1295 + Ipamorelin
Add all 3 items to your cart
$345
References
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed: 17018654
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed: 16352683
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822
- Gobburu JV, Agersu00f8 H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed: 10496658
